'Someone should oversee it': Patient perspectives on the ethical issues arising with the regulation of probiotics

Krista L. Harrison, Ruth M. Farrell, Margaret A. Brinich, Janelle Highland, Marybeth Mercer, Jennifer B. Mccormick, Jon Tilburt, Gail Geller, Patricia Marshall, Richard R. Sharp

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Although many probiotic products are currently available in yogurt or pill form in the United States (US), there is uncertainty surrounding the structure of regulation of these products. As more therapeutic probiotics are developed, changes to existing regulatory process in the United States may be required to meet the needs of patients and users in the population. Objective: This study examined how patients with chronic gastrointestinal (GI) diseases view the regulation of probiotics. Design: We conducted a multi-site qualitative study consisting of focus groups of patients with chronic gastrointestinal diseases at three tertiary hospitals: at [institutions removed for blinded review]. Results: We conducted 22 focus groups with 136 patients with major gastrointestinal (GI) diseases between March and August 2009. Participants were not familiar with the existing regulation of probiotic products but wanted assurances of accurate labelling of strain as well as safety. Participants raised concerns that regulation of probiotics might be accompanied by greater costs, reduced access and increased involvement of pharmaceutical companies. Although participants voiced significant doubt of government regulators, they felt that products containing genetically modified probiotic strains should have oversight comparable to that of pharmaceutical drugs. Discussion and conclusion: If GI patient perspectives are indicative of public perceptions of therapeutic probiotics in the United States, consumers may expect more rigorous regulation in the future while simultaneously wanting low costs, easy access and low involvement of pharmaceutical companies. Manufacturers, translational scientists, clinicians and regulators should be sensitive to consumer attitudes when designing, testing and regulating new therapeutic probiotics.

Original languageEnglish (US)
Pages (from-to)250-261
Number of pages12
JournalHealth Expectations
Volume18
Issue number2
DOIs
StatePublished - Apr 1 2015

Fingerprint

Probiotics
Ethics
Gastrointestinal Diseases
Focus Groups
Pharmaceutical Preparations
Chronic Disease
Costs and Cost Analysis
Yogurt
Tertiary Care Centers
Uncertainty
Therapeutics
Safety
Population

All Science Journal Classification (ASJC) codes

  • Public Health, Environmental and Occupational Health

Cite this

Harrison, Krista L. ; Farrell, Ruth M. ; Brinich, Margaret A. ; Highland, Janelle ; Mercer, Marybeth ; Mccormick, Jennifer B. ; Tilburt, Jon ; Geller, Gail ; Marshall, Patricia ; Sharp, Richard R. / 'Someone should oversee it' : Patient perspectives on the ethical issues arising with the regulation of probiotics. In: Health Expectations. 2015 ; Vol. 18, No. 2. pp. 250-261.
@article{d8276c753fd84b0581190aa6171121aa,
title = "'Someone should oversee it': Patient perspectives on the ethical issues arising with the regulation of probiotics",
abstract = "Background: Although many probiotic products are currently available in yogurt or pill form in the United States (US), there is uncertainty surrounding the structure of regulation of these products. As more therapeutic probiotics are developed, changes to existing regulatory process in the United States may be required to meet the needs of patients and users in the population. Objective: This study examined how patients with chronic gastrointestinal (GI) diseases view the regulation of probiotics. Design: We conducted a multi-site qualitative study consisting of focus groups of patients with chronic gastrointestinal diseases at three tertiary hospitals: at [institutions removed for blinded review]. Results: We conducted 22 focus groups with 136 patients with major gastrointestinal (GI) diseases between March and August 2009. Participants were not familiar with the existing regulation of probiotic products but wanted assurances of accurate labelling of strain as well as safety. Participants raised concerns that regulation of probiotics might be accompanied by greater costs, reduced access and increased involvement of pharmaceutical companies. Although participants voiced significant doubt of government regulators, they felt that products containing genetically modified probiotic strains should have oversight comparable to that of pharmaceutical drugs. Discussion and conclusion: If GI patient perspectives are indicative of public perceptions of therapeutic probiotics in the United States, consumers may expect more rigorous regulation in the future while simultaneously wanting low costs, easy access and low involvement of pharmaceutical companies. Manufacturers, translational scientists, clinicians and regulators should be sensitive to consumer attitudes when designing, testing and regulating new therapeutic probiotics.",
author = "Harrison, {Krista L.} and Farrell, {Ruth M.} and Brinich, {Margaret A.} and Janelle Highland and Marybeth Mercer and Mccormick, {Jennifer B.} and Jon Tilburt and Gail Geller and Patricia Marshall and Sharp, {Richard R.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1111/hex.12027",
language = "English (US)",
volume = "18",
pages = "250--261",
journal = "Health Expectations",
issn = "1369-6513",
publisher = "Wiley-Blackwell",
number = "2",

}

Harrison, KL, Farrell, RM, Brinich, MA, Highland, J, Mercer, M, Mccormick, JB, Tilburt, J, Geller, G, Marshall, P & Sharp, RR 2015, ''Someone should oversee it': Patient perspectives on the ethical issues arising with the regulation of probiotics', Health Expectations, vol. 18, no. 2, pp. 250-261. https://doi.org/10.1111/hex.12027

'Someone should oversee it' : Patient perspectives on the ethical issues arising with the regulation of probiotics. / Harrison, Krista L.; Farrell, Ruth M.; Brinich, Margaret A.; Highland, Janelle; Mercer, Marybeth; Mccormick, Jennifer B.; Tilburt, Jon; Geller, Gail; Marshall, Patricia; Sharp, Richard R.

In: Health Expectations, Vol. 18, No. 2, 01.04.2015, p. 250-261.

Research output: Contribution to journalArticle

TY - JOUR

T1 - 'Someone should oversee it'

T2 - Patient perspectives on the ethical issues arising with the regulation of probiotics

AU - Harrison, Krista L.

AU - Farrell, Ruth M.

AU - Brinich, Margaret A.

AU - Highland, Janelle

AU - Mercer, Marybeth

AU - Mccormick, Jennifer B.

AU - Tilburt, Jon

AU - Geller, Gail

AU - Marshall, Patricia

AU - Sharp, Richard R.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Background: Although many probiotic products are currently available in yogurt or pill form in the United States (US), there is uncertainty surrounding the structure of regulation of these products. As more therapeutic probiotics are developed, changes to existing regulatory process in the United States may be required to meet the needs of patients and users in the population. Objective: This study examined how patients with chronic gastrointestinal (GI) diseases view the regulation of probiotics. Design: We conducted a multi-site qualitative study consisting of focus groups of patients with chronic gastrointestinal diseases at three tertiary hospitals: at [institutions removed for blinded review]. Results: We conducted 22 focus groups with 136 patients with major gastrointestinal (GI) diseases between March and August 2009. Participants were not familiar with the existing regulation of probiotic products but wanted assurances of accurate labelling of strain as well as safety. Participants raised concerns that regulation of probiotics might be accompanied by greater costs, reduced access and increased involvement of pharmaceutical companies. Although participants voiced significant doubt of government regulators, they felt that products containing genetically modified probiotic strains should have oversight comparable to that of pharmaceutical drugs. Discussion and conclusion: If GI patient perspectives are indicative of public perceptions of therapeutic probiotics in the United States, consumers may expect more rigorous regulation in the future while simultaneously wanting low costs, easy access and low involvement of pharmaceutical companies. Manufacturers, translational scientists, clinicians and regulators should be sensitive to consumer attitudes when designing, testing and regulating new therapeutic probiotics.

AB - Background: Although many probiotic products are currently available in yogurt or pill form in the United States (US), there is uncertainty surrounding the structure of regulation of these products. As more therapeutic probiotics are developed, changes to existing regulatory process in the United States may be required to meet the needs of patients and users in the population. Objective: This study examined how patients with chronic gastrointestinal (GI) diseases view the regulation of probiotics. Design: We conducted a multi-site qualitative study consisting of focus groups of patients with chronic gastrointestinal diseases at three tertiary hospitals: at [institutions removed for blinded review]. Results: We conducted 22 focus groups with 136 patients with major gastrointestinal (GI) diseases between March and August 2009. Participants were not familiar with the existing regulation of probiotic products but wanted assurances of accurate labelling of strain as well as safety. Participants raised concerns that regulation of probiotics might be accompanied by greater costs, reduced access and increased involvement of pharmaceutical companies. Although participants voiced significant doubt of government regulators, they felt that products containing genetically modified probiotic strains should have oversight comparable to that of pharmaceutical drugs. Discussion and conclusion: If GI patient perspectives are indicative of public perceptions of therapeutic probiotics in the United States, consumers may expect more rigorous regulation in the future while simultaneously wanting low costs, easy access and low involvement of pharmaceutical companies. Manufacturers, translational scientists, clinicians and regulators should be sensitive to consumer attitudes when designing, testing and regulating new therapeutic probiotics.

UR - http://www.scopus.com/inward/record.url?scp=84925357813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925357813&partnerID=8YFLogxK

U2 - 10.1111/hex.12027

DO - 10.1111/hex.12027

M3 - Article

C2 - 23279082

AN - SCOPUS:84925357813

VL - 18

SP - 250

EP - 261

JO - Health Expectations

JF - Health Expectations

SN - 1369-6513

IS - 2

ER -